Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Survival rates for incurable larynx cancer investigated for first time

2.

findings from the measurement of disability weights in China with an emphasis on the impact of disease burden.

3.

Knowing about and avoiding bladder cancer.

4.

The risk of ovarian cancer is not increased by salpingectomy, according to JAMA.

5.

Aspirin Fails to Boost Survival in Colorectal Cancer Trial


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot